Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Pfizer Japan Ups Oncology Sales Force, Reorganizes It into Blood, Solid Cancer Groups
June 27, 2017
- Unauthorized Additive Used for Yamamoto Chemical’s Zonisamide
June 27, 2017
- Sumitomo Dainippon’s Napabucasin Stumbles on PIII Gastric Cancer Study
June 27, 2017
- Fujifilm, CanBas Pair Up for Joint Research on Peptide-Based Cancer Immunotherapies
June 27, 2017
- Daiichi Sankyo Confident of Achieving US$1 Billion Sales for Edoxaban
June 26, 2017
- FDA Snubs Takeda/Lundbeck’s Reattempt for Trintellix Label Expansion
June 26, 2017
- Eisai Seeks HCC Indication for Lenvima in Japan
June 26, 2017
- Kyowa Kirin, LEO Pharma Tie Up for Gel Version of Dovobet Too
June 23, 2017
- Bioverativ Japan Files 4,000 IU Version for Hemophilia B Treatment Alprolix
June 23, 2017
- Development Race Heating Up for HIF-PH Inhibitors, Promising Alternative to ESAs in Renal Anemia Space?
June 22, 2017
- EA Pharma to Discontinue Lentinan Sales amid Dwindling Demand
June 22, 2017
- Atsuo Takahashi Becomes Toa Eiyo President
June 22, 2017
- Takeda’s New Solid Dosage Form Production Facilities Completed in Germany
June 21, 2017
- Zeria to Terminate Development of Novel PPI
June 21, 2017
- Seikagaku Begins US PII Study of SI-613 for Knee Osteoarthritis
June 21, 2017
- Mitsubishi Tanabe Wins Fingolimod Patent Infringement Lawsuit in US
June 21, 2017
- Amgen Astellas Biopharma Gearing Up for 2020 Takeoff as Stand-Alone Subsidiary
June 20, 2017
- Takecab Most Heavily Promoted Drug for Hospital Doctors in April: Anterio
June 19, 2017
- Biogen Japan Upbeat on Tecfidera, Near-Approval Nusinersen, Sakigake Boost for Aducanumab
June 19, 2017
- Kaken, Numab Strike Deal for Multi-Specific Antibody in Inflammatory Disease
June 14, 2017
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…